Filed on behalf of Coalition for Affordable Drugs VIII, LLC

By: Dr. Gregory Gonsalves Reg. No. 43,639 2216 Beacon Lane Falls Church, Virginia 22043 (571) 419-7252 gonsalves@gonsalveslawfirm.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS VIII, LLC, Petitioner

v.

TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,

Patent Owner, based on Electronic Records of PTO U.S. Patent 8,618,135 to Rader Filing Date: March 11, 2011

Issue Date: December 31, 2013

TITLE: METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS

IPR Trial No. <u>TBD</u>

Petition for Inter Partes Review of U.S. Patent No. 8,618,135

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450



TABLE OF CONTENTS

I.	MANDATORY NOTICES UNDER 37 C.F.R. § 42.81					
	A.	Real	Party-in-Interest (37 C.F.R. § 42.8(B)(1))	1		
	B.	Rela	ated Matters (37 C.F.R. § 42.8(b)(2))	3		
	C.	Noti	ce of Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3))	3		
	D.	Serv	vice Information under 37 C.F.R. § 42.8(b)(4)	3		
	E.		vice on Patent Owner Under 37 C.F.R. §§ 42.106(a) and 05(a)	3		
II.	GRO	OUND	S FOR STANDING UNDER 37 C.F.R. § 42.104(A)	4		
III.	IDE	NTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(B))4				
IV.	INT	RODUCTION AND SUMMARY OF ARGUMENT5				
V.	THE '135 PATENT PRIORITY DATE IS MARCH 7, 2005; THE '915 PROVISIONAL DOES NOT SUPPORT THE ISSUED CLAIMS.					
	A.	No S	Support for the Full Scope of the Claimed Dose Ranges	8		
	B.	In A	ddition, No Support for "the Piperidine N-oxide Thereof"	10		
VI.	SCOPE AND CONTENT OF THE PRIOR ART12					
	A.	Elevated Serum Cholesterol and Lipid Levels Were Recognized Risk Factors For Cardiovascular Disease				
	B.	Kno	wn Drug Classes and Dosing Regimens Pre-March 2003	12		
	C.	C. The Content of the MTP Inhibitor Art Pre-March 2004				
		1.	Pink Sheet 2004 is Prior Art.	15		
		2.	Stein's 2004 Presentation – Published Before March 5, 2004 and Again by At Least April 15, 2004 – is Prior	1.0		
			Art	16		



		3.	The Prior Art Taught Step-Wise MTP Inhibitor Dosing Over Seven Levels; the Rationale; and Expected Efficacy.	22	
VII.	U.S. PATENT NO. 8,618,135 AND ITS FILE HISTORY				
	A.		135 Patent Repeats Information Already Known to narily-Skilled Artisans.	24	
	B.	The '	135 Patent File History.	26	
	C.	The H	European Opposition Proceedings	28	
VIII.	THE	LEVE	L OF ORDINARY SKILL IN THE ART	28	
IX.		AIM CONSTRUCTION STATEMENT (37 C.F.R. 2.104(B)(3))			
X.	EXPLANATION OF GROUNDS FOR UNPATENTABILITY				
	A.	Ground I: Obviousness Over Pink Sheet 2004 in View of Chang			
		1.	The Claimed Lomitapide Escalating-Dosing Approach was Already Taught for Implitapide	32	
		2.	Motivation to Combine Pink Sheet 2004 with Chang	39	
		3.	Reasonable Expectation of Success With Lomitapide	43	
	B.	Ground II: Obviousness Over Stein 2004 in View of Chang			
		1.	There Are No Non-Obvious Differences	46	
		2.	Motivation to Combine Stein 2004 with Chang	53	
		3.	Reasonable Expectation of Success With Lomitapide	55	
	C.	C. Secondary Considerations Presented During Prosecution Do Not Rebut the <i>Prima Facie</i> Case of Unpatentability			
XI.	CONCLUSION				



EXHIBIT LIST PURSUANT TO 37 C.F.R. § 42.63(e) AND TABLE OF ABBREVIATIONS



Ex. No.	Description
1001	Certified U.S. Patent No. 8,618,135 to Rader.
1002	Declaration of Randall M. Zusman, M.D.
1003	Declaration of Michael Mayersohn, Ph.D.
1004	Affidavit of Christopher Butler, Office Manager, Internet Archive, authenticating Internet Archive URLs (June 16, 2015) (attaching as Ex. A:
	PPD News & IR Presentations (2004/04/15) (available at https://web.archive.org/web/20040415065142/http://ppdi.com/PPD_6_12.htm)).
1005	Affidavit of Christopher Butler, Office Manager, Internet Archive, authenticating Internet Archive URLs (June 12, 2015) (attaching as Ex. A:
	PPD News Releases(2004/02/13) (available at https://web.archive.org/web/20040213233245/http://www.ppdi.com/PPD_U6.htm?ID=126662);
	PPD News & IR Presentations(2003/12/12) (available at https://web.archive.org/web/20031212193444/http://ppdi.com/PPD_6 _12.htm);
	PPD News & IR Presentations (2004/06/04) (available at https://web.archive.org/web/20040604203252/http://www.ppdi.com/PPD_6_12.htm)).
1006	Certified U.S. Provisional Patent Application No. 60/550,915.
1007	U.S. Patent No. 8,618,135 (highlighting dosing information not present in U.S. Provisional Patent Application No. 60/550,915).
1008	U.S. Patent Application No. 13/046,118.
1009	In re Application of: Rader, U.S. Patent Application No. 13/046,118, Amendment and Response to Oct. 2, 2012 Office Action (Mar. 4, 2013).



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

